Taro Pharmaceutical Industries (NYSE:TARO) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO) in a research note released on Friday. The firm issued a strong-buy rating on the stock.

Separately, HC Wainwright cut Taro Pharmaceutical Industries from a buy rating to a neutral rating and set a $43.00 target price for the company. in a research note on Thursday, January 18th.

Taro Pharmaceutical Industries Trading Up 0.1 %

Shares of TARO stock opened at $42.25 on Friday. The stock has a market cap of $1.59 billion, a P/E ratio of 34.63 and a beta of 0.61. The stock has a 50 day simple moving average of $42.13 and a 200 day simple moving average of $39.82. Taro Pharmaceutical Industries has a 1 year low of $24.39 and a 1 year high of $45.76.

Taro Pharmaceutical Industries (NYSE:TARO) last issued its quarterly earnings results on Thursday, January 25th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.26. The business had revenue of $157.15 million during the quarter, compared to analysts’ expectations of $154.90 million. Taro Pharmaceutical Industries had a return on equity of 3.26% and a net margin of 7.48%. Analysts forecast that Taro Pharmaceutical Industries will post 1.38 EPS for the current year.

Institutional Investors Weigh In On Taro Pharmaceutical Industries

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Krensavage Asset Management LLC bought a new stake in Taro Pharmaceutical Industries during the first quarter worth $15,611,000. BlackRock Inc. lifted its stake in shares of Taro Pharmaceutical Industries by 265.5% in the 2nd quarter. BlackRock Inc. now owns 581,838 shares of the company’s stock valued at $22,069,000 after acquiring an additional 422,645 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Taro Pharmaceutical Industries by 0.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 572,905 shares of the company’s stock valued at $13,933,000 after acquiring an additional 2,535 shares during the last quarter. Brandes Investment Partners LP lifted its stake in shares of Taro Pharmaceutical Industries by 0.7% in the 4th quarter. Brandes Investment Partners LP now owns 475,741 shares of the company’s stock valued at $19,876,000 after acquiring an additional 3,253 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in shares of Taro Pharmaceutical Industries by 32.2% in the 3rd quarter. Ameriprise Financial Inc. now owns 304,309 shares of the company’s stock valued at $11,475,000 after acquiring an additional 74,054 shares during the last quarter. 91.40% of the stock is currently owned by institutional investors.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.